These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 14587161)

  • 21. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
    Follath F; Franco F; Cardoso JS
    Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levosimendan in two neonates with ischemic heart failure and pulmonary hypertension.
    De Carolis MP; Piastra M; Bersani I; Pardeo M; Stival E; Tempera A; Romagnoli C; Conti G; De Rosa G
    Neonatology; 2012; 101(3):201-5. PubMed ID: 22067520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
    Erhardt LR
    Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
    Duygu H; Ozerkan F; Zoghi M; Nalbantgil S; Yildiz A; Akilli A; Akin M; Nazli C; Ergene O
    Int J Clin Pract; 2008 Feb; 62(2):228-33. PubMed ID: 17949428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newer approaches to the pharmacological management of heart failure.
    Rauch H; Motsch J; Böttiger BW
    Curr Opin Anaesthesiol; 2006 Feb; 19(1):75-81. PubMed ID: 16547437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New pharmacologic therapies for acute heart failure.
    Tavares M; Rezlan E; Vostroknoutova I; Khouadja H; Mebazaa A
    Crit Care Med; 2008 Jan; 36(1 Suppl):S112-20. PubMed ID: 18158470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a place for levosimendan in the intensive care unit?
    Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
    Crit Care Resusc; 2007 Sep; 9(3):290-2. PubMed ID: 17767458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 36. Levosimendan in heart failure after surgical repair of cardiac rupture.
    Torrado H; Ventura JL; Ruiz-Majoral A; Farrero E; Rodriguez-Castro D; Carrio ML; Miralles A
    Minerva Cardioangiol; 2009 Feb; 57(1):137-8. PubMed ID: 19202525
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety of levosimendan and other calcium sensitizers.
    Lehtonen L; Mills-Owens P; Akkila J
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S70-6. PubMed ID: 8907134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levosimendan: a new option in acute septic cardiac failure?
    Powell BP; De Keulenaer B
    Emerg Med Australas; 2007 Apr; 19(2):177; author reply 177-8. PubMed ID: 17448109
    [No Abstract]   [Full Text] [Related]  

  • 39. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
    Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
    Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levosimendan reversing low output syndrome after heart transplantation.
    Petäjä LM; Sipponen JT; Hämmäinen PJ; Eriksson HI; Salmenperä MT; Suojaranta-Ylinen RT
    Ann Thorac Surg; 2006 Oct; 82(4):1529-31. PubMed ID: 16996977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.